Albatros 2025-Treat alcoholism thanks to GLP-1’s agonists?

PARIS — Do GLP-1 receptor agonists have an effect on reducing alcoholic consumption? Similarly, This question was at the center of a speech of Pr Anders Fink-Jeansen. Meanwhile. Moreover, Head of Service of the Copenhagen Psychiatric Hospital Center, Professor of Psychiatry and Director of the Neuropsychiatry Laboratory at the University of CopenhagenJune 11 During the Albatros Congress which took place in Paris.

“In 2011, we collaborated with a teacher working in a hospital north of Copenhagen, where the population is generally easy. Nevertheless, Many people from this region regularly participate in wine tastings in Italy, France, etc. Furthermore, And some of them, treated with the GLP-1 receptor agonists, reported a drop in their interest in alcohol. Therefore, Swedish. Moreover. Therefore, American researchers albatros 2025-treat alcoholism thanks glp-1’s new have found it interesting and returned to the laboratory to carry out tests to study disorders related albatros 2025-treat alcoholism thanks glp-1’s to alcohol consumption and their treatment ”starts Professor Anders Fink-Jeansen begins. Furthermore, “The first fabricated agonist actually came from the saliva of the Gila monster. Therefore, a reptile living in the desert of the New Mexico. Moreover, It was developed under the name of Exénatide. Furthermore, the first agonist of the GLP-1 receiver used in clinic »he continues. Nevertheless, “” Many initial preclinical pharmacological studies have been carried out with exenatide by a Swedish pharmaceutical group. In addition, which demonstrated in 2013 a decrease in alcohol consumption at very low doses of exenatide, or 400 micrograms per kilo. However, »»

Decrease in dopamine – Albatros 2025-treat alcoholism thanks glp-1's – Albatros 2025-treat alcoholism thanks glp-1's new

Exenatide has also been studied in the context of cocaine consumption. “We have albatros 2025-treat alcoholism thanks glp-1’s new made a microanalysis on rats and observed a modification of dopamine levels. Cocaine considerably increases dopamine levels. which we have been albatros 2025-treat alcoholism thanks glp-1’s able to inhibit by precontrol in exenatide. At the time. it was assumed that the decrease in dopamine levels could be attributed to a positive regulation of the transporter. of dopamine ”he explains. The exenatide was then tested in monkeys consumers of alcohol: “A low dose of exenatide decreases alcohol. consumption compared to placebo. Likewise, Liraglutide significantly reduces low -dose alcohol consumption in another study ”.

Randomized double blind study – Albatros 2025-treat alcoholism thanks glp-1's new

The decision was then made to conduct a randomized double blind. study On the effects of exénatide concerning the reduction in alcohol consumption. This study of a semester was carried out with 127 patients dependent on alcohol. consultant in a clinic in the Copenhagen region. “Their average weight albatros 2025-treat alcoholism thanks glp-1’s new was 82 kilos, with a BMI (body mass index) greater than 18.5. They were neither very thin nor albatros 2025-treat alcoholism thanks glp-1’s obese ”specifies Professor Fink-Jeansen. No notable difference was noted between the 2 groups in terms of alcohol consumption. With the exception of patients whose BMI was greater than 25: “First of all. no global effect was found throughout the group. but an effect was observed in obese people, or those with a BMI greater than 25, namely a spectacular reduction in the number of days of high alcohol consumption. In addition, after treatment, a significant reduction in mental tension was observed at the end of the 26 weeks of experience. This suggests a changing to the cerebral level ”concludes Professor Fink-Jeansen.

This study then tested another agonist. semaglutide, on alcohol consumption in monkeys : “This medication, administered each week, seems more effective albatros 2025-treat alcoholism thanks glp-1’s new than exenatide for diabetes. It is available according to 2 formulations: a dose of 1 mg for albatros 2025-treat alcoholism thanks glp-1’s type 2 diabetes. Wegovy at 2.4 mg to treat obesity. We have tested its effects on the monkeys. We measured their blood alcohol level for 3 weeks. In one of the groups, we injected them twice a week for semaglutide, increasing the 0.01 mg dose to 0.03 mg, then 0.04 mg, 0.05 mg. Then, we measured alcohol consumption over 3 weeks, before stopping the current medical treatment for a week’s withdrawal period. Two weeks before starting the treatment with semaglutide or placebo, no difference has been observed. The results of weeks 1. 2. 3 show a significant decrease in alcohol consumption in subjects treated with semaglutide, compared to the subjects that received a placebo. With this convincing primary data, We have undertaken a study with alcohol albatros 2025-treat alcoholism thanks glp-1’s new dependent people and damage to morbid obesity. We are about to finalize this study in August albatros 2025-treat alcoholism thanks glp-1’s this year. hope to be able to present detailed data by the end of the year “detailed Professor Fink-Jeansen. He concluded, with optimism: “We hope to convince medical companies to take an interest in this area. Although pharmaceutical companies have neglected this sector, we want to change this in the future. »»

What did you remember from this article? Realize this quiz To find out.